| 23.73 -2.54 (-9.67%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.06 |
1-year : | 31.58 |
| Resists | First : | 24.88 |
Second : | 27.04 |
| Pivot price | 24.2  |
|||
| Supports | First : | 21.39 |
Second : | 17.8 |
| MAs | MA(5) : | 25.37 |
MA(20) : | 23.73 |
| MA(100) : | 24.75 |
MA(250) : | 28.68 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 70.8 |
D(3) : | 81.2 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 37.84 | Low : | 21 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ENOV ] has closed above bottom band by 40.4%. Bollinger Bands are 14.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 26.67 - 26.84 | 26.84 - 26.96 |
| Low: | 23.37 - 23.56 | 23.56 - 23.69 |
| Close: | 23.48 - 23.76 | 23.76 - 23.95 |
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Sat, 18 Apr 2026
Does The Recent Rebound In Enovis (ENOV) Share Price Reflect Its True Worth? - Yahoo Finance
Fri, 17 Apr 2026
ENOV Assumed by William Blair -- Rating Maintained as Outperform - GuruFocus
Fri, 17 Apr 2026
Analyst Backs Enovis On Cash Flow Turnaround - Benzinga
Fri, 17 Apr 2026
Enovis Coverage Assumed by William Blair at Outperform - Moomoo
Fri, 17 Apr 2026
William Blair Initiates Enovis Corp(ENOV.US) With Buy Rating - 富途牛牛
Tue, 14 Apr 2026
Is It Time To Reconsider Enovis (ENOV) After Recent Share Price Rebound - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Industrials
|
|
|
Industry:
Industrial - Machinery
|
|
| Shares Out | 58 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 117.3 (%) |
| Shares Short | 8,150 (K) |
| Shares Short P.Month | 8,040 (K) |
| EPS | -20.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 26.04 |
| Profit Margin | -52.7 % |
| Operating Margin | 6 % |
| Return on Assets (ttm) | 1 % |
| Return on Equity (ttm) | -58.3 % |
| Qtrly Rev. Growth | 2.5 % |
| Gross Profit (p.s.) | 23.8 |
| Sales Per Share | 39.1 |
| EBITDA (p.s.) | 6.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 217 (M) |
| Levered Free Cash Flow | 104 (M) |
| PE Ratio | -1.15 |
| PEG Ratio | 3.4 |
| Price to Book value | 0.91 |
| Price to Sales | 0.6 |
| Price to Cash Flow | 6.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|